Study CGRP blocker effects on migraine and body nerve function
Treatments studied
Part of Brain & nervous system, Pain clinical trials.
This study tests a CGRP-blocking antibody to see how it affects migraine symptoms and the body’s automatic (involuntary) nerve functions. It may help people with migraine who have already tried several preventive medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have migraine that is either chronic, or episodic with or without aura
- You’ve already tried at least 3 preventive (pre-migraine) medicines without enough success
- Your health insurance covers the study medicine costs
- If you are a healthy control (not a migraine patient): you must have no diagnosed chronic illness and no recent infection needing medicine
- You should not be pregnant, and you should not be breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at the chemical changes in the blood of people with migraine. It aims to better understand the disease and may help find new treatments. You may qualify if you have episodic or chronic migraine and have not tried CGRP-targeting drugs.
This study looks at how preventive treatments (botulinum toxin type A or anti-CGRP antibodies) affect thinking, memory, and quality of life in adults with hard-to-treat migraines. It aims to see if these treatments help more than just reducing headache days.
This study is building a database to learn more about migraine drugs. It may help researchers find better treatments for people with episodic or chronic migraine.
This study tracks how well new migraine medications (like Aimovig, Emgality, Ajovy, Vyepti, Qulipta, and Nurtec) work in everyday use. It may help you and your doctor understand if these treatments are a good option for your migraines.
This trial is testing new approaches for people whose migraines haven't improved with multiple preventive treatments. The goal is to find better options for those with hard-to-treat migraine.
This study looks for new biological markers in people whose migraines don't respond to standard treatments. It aims to better understand why some migraines are hard to treat and may help guide future therapies.
Hear when a new Episodic Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.